Sept. 12 Company Quick Takes: Atomwise in China deal; plus Ardelyx, GSK, Amarin, deCode
Atomwise, Hansoh in AI drug discovery deal
AI-based drug discovery company Atomwise Inc. (San Francisco, Calif.) has partnered with Hansoh Pharmaceutical Group Co. Ltd. (Jiangsu, China) to design and develop drug candidates against up to 11 undisclosed targets. Atomwise is eligible to receive $1.5 billion under the deal, its first in Asia. Financial details are not disclosed.
FDA approves Ardelyx’s tenapanor for IBS-C
Ardelyx Inc. (NASDAQ:ARDX) gained its first product approval Thursday as FDA approved Ibsrela tenapanor to treat irritable bowel syndrome with constipation. The approval follows last week’s positive data for the solute carrier family 9 sodium hydrogen exchanger member 3 (SLC9A3; NHE3) inhibitor in hyperphosphatemia in end-stage renal disease (ESRD) patients (see “Ardelyx Gains on Phase III Hyperphosphatemia Combination Data”)...